InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) shares traded -46.48% lower at $1.14 on Wall Street last session.
In accordance with the data, 1 analysts cover InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $937.50 and a low of $937.50, we find $937.50. Given the previous closing price of $2.13, this indicates a potential upside of 43914.08 percent. NVIV stock price is now -48.88% away from the 50-day moving average and -68.93% away from the 200-day moving average. The market capitalization of the company currently stands at $2.19M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
It has been rated a hold by 0 analysts and a buy by 1. Brokers who have rated the stock have averaged $937.50 as their price target over the next twelve months.
, while ‘Ladenburg Thalmann’ rates the stock as ‘Buy’.
A total of 0.22% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NVIV stock. A new stake in InVivo Therapeutics Holdings Corp. shares was purchased by ARMISTICE CAPITAL, LLC during the first quarter worth $253,000. In total, there are 17 active investors with 8.60% ownership of the company’s stock.
InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) opened at $1.2000 on Thursday. During the past 12 months, InVivo Therapeutics Holdings Corp. has had a low of $1.61 and a high of $13.77. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.60, and a quick ratio of 4.60. The fifty day moving average price for NVIV is $2.2318 and a two-hundred day moving average price translates $3.6699 for the stock.
The latest earnings results from InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) was released for Sep, 2022.
InVivo Therapeutics Holdings Corp.(NVIV) Company Profile
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
Leave a Reply